参考文献：[1] Malumbres, M (2007). CDK inhibitors in cancer therapy: what is next? TRENDS in Pharmacological Sciences Vol.29 No.1. 16-21 [2] Finn, R. PD0332991, a Selective Cyclin D Kinase 4/6 Inhibitor, Preferentially Inhibits Proliferation of Luminal Estrogen Receptor-Positive Human Bre...
Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137(10):1409–1418. : 10.1007/s00432-011-1039-4Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011; 137 (10):1409–...
参考文献: [1] Malumbres, M (2007). CDK inhibitors in cancer therapy: what is next? TRENDS in Pharmacological Sciences Vol.29 No.1. 16-21 [2] Finn, R. PD0332991, a Selective Cyclin D Kinase 4/6 Inhibitor, Preferentially Inhibits Proliferation of Luminal Estrogen Receptor-Positive Human Br...
3. Stephin J. Vervoort, et al. Targeting transcription cycles in cancer. Nature Reviews Cancer. 2021, https://doi.org/10.1038/s41568-021-00411-8 4. Muhammad Jameel Mughal, Kinjal Bhadresha and Hang Fai Kwok, CDK inhibitors from past to present: a new wave of cancer therapy, Seminars i...
[2] Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. J Med Chem, 2019. DOI: 10.1021/acs.jmedchem.8b01469. [3] Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today, 2019. DOI: 10.1016/j.drudis.2019.12.001. ...
12、Li, Guo et al. “The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.” Frontiers in cell and developmental biology vol. 8 576946. 29 Sep. 2020, doi:10.3389/fcell.2020.576946 袁芃 教授 ...
借助2019年在国际药物化学顶刊JCO上一篇文章Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update学习、理解CDK2抑制剂。 细胞周期蛋白依赖性激酶2(CDK2)驱动细胞进入细胞周期的S期和M期。CDK2活性对于正常发育在很大程度上是可有可无的,但它...
The toxicity profile varies between different CDK4/6 inhibitors, allowing a degree of treatment tailoring based on the needs of individual patients. The increased and earlier use of CDK4/6 inhibitors has resulted in a better understanding of the mechanisms of acquired resistance; potential treatment...
Targeting cyclin-dependent kinase 9 in cancer therapy CDK9 activation in cancer cells,CDK9 inhibitors have emerged as promising candidates for cancer therapy.Natural product-derived and chemically synthesized CDK9... Yi-li Shen,Yan-mao Wang,Ya-xin Zhang,Shen-jie Ma,Le-he Yang,Cheng-guang Zhao...
CDK4/6 inhibitors are most effective in combination with endocrine therapy in patients with HR-positive breast cancer: preclinical data support the combination of CDK4/6 inhibitors with PI3K and/or MAPK inhibitors Loss of RB1 function is an established mechanism of primary resistance to CDK4/6 ...